Results 261 to 270 of about 45,139 (271)
Some of the next articles are maybe not open access.
Transthyretin and the Transthyretin Amyloidoses
2007Transthyretin is a normal serum protein that carries the secondary thyroid hormone thyroxine and retinol binding protein when it is loaded with retinol. It is synthesized primarily in the liver but there is also significant production in the choroid plexus and the retina. Both message and protein are found in the kidney but that site does not appear to
openaire +2 more sources
Cardiac transthyretin amyloidosis
Heart, 2012Cardiac amyloidosis of transthyretin fibril protein (ATTR) type is an infiltrative cardiomyopathy characterised by ventricular wall thickening and diastolic heart failure. Increased access to cardiovascular magnetic resonance imaging has led to a marked increase in referrals to our centre of Caucasian patients with wild-type ATTR (senile systemic ...
Jason Dungu +3 more
openaire +2 more sources
Localization of transthyretin-mRNA and of immunoreactive transthyretin in the human fetus
Virchows Archiv A Pathological Anatomy and Histopathology, 1989Five human fetuses at mid-term (16-20 weeks) and one with a gestational age of 8 weeks were investigated. The cellular localization of transthyretin (TTR)-mRNA in different organs was demonstrated by in situ hybridization with a 35S-labelled, single-stranded RNA probe. Immunoreactive TTR (TTR-IR) was localized with a monoclonal antibody to TTR.
openaire +3 more sources
Transthyretin Mass Determination for Detection of Transthyretin Familial Amyloid
2009The concentration range of plasma proteins exceeds the dynamic range of any single analytical method. It has been estimated that the concentration range of serum proteins exceeds ten orders of magnitude (1). Because of this, prior immunoselection of even abundant proteins facilitates the relative nonquantitative observations required to show structural
John F. O'Brien, H. Robert Bergen
openaire +3 more sources
Tafamidis for transthyretin amyloidosis
Drugs of Today, 2012Tafamidis meglumine (Vyndaqel®, Pfizer) is a novel, first-in-class drug for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare neurodegenerative disorder characterized by progressive sensory, motor and autonomic impairment that is ultimately fatal.
openaire +3 more sources
Pathogenesis of transthyretin amyloidosis
Amyloid, 2012Current dogma for transthyretin (TTR) pathogenesis is that mutations in TTR alter its structure such that the tetramer becomes unstable and prone to release of monomer which then becomes the putative building block of the fibril. This hypothesis is supported by thermodynamic data showing decreased stability of mutant TTR tetrameric proteins and ...
openaire +2 more sources
Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy
Annals of Pharmacotherapy, 2019Objective: To review the pharmacology, efficacy, and safety of the selective transthyretin inhibitor tafamidis for transthyretin amyloid cardiomyopathy (ATTR-CM). Data Sources: A PubMed (1966 to October 2019) and ClinicalTrials. gov search was conducted using the keywords tafamidis, Fx-1006A, Vyndaqel, and Vyndamax.
Jonathan Park +5 more
openaire +2 more sources
Transthyretin in bladder cancer
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2020Ming Zhang +4 more
openaire +3 more sources
Transthyretin amyloid cardiomyopathy
The American Journal of the Medical Sciences, 2023Giuseppe, Famularo, Guido, Ventroni
openaire +2 more sources